Pathogenese und Therapie des akuten Koronarsyndroms differenzieller Nutzen von GPIIb/IIIa-Rezeptorantagonisten bei Hochrisikopatienten

Zusammenfassung

Für die Pathophysiologie des akuten Koronarsyndroms spielen aktivierte Thrombozyten und deren Aggregation zu einem Thrombus eine entscheidende Rolle. Glykoprotein-IIb/IIIa-Rezeptorantagonisten (GPIIb/IIIa-Rezeptorantagonisten) blockieren die Bindung von Fibrinogen an GPIIb/IIIa-Rezeptoren aktivierter Thrombozyten und verhindern deren Aggregation. Patienten mit akutem Koronarsyndrom und erhöhten Troponin-Werten, die einer primären Revaskularisierung unterzogen werden sollen, haben einen besonderen Nutzen von einer Behandlung mit GPIIb/IIIa-Rezeptorantagonisten. Dies gilt auch und insbesondere für Diabetiker.

Summary

Pathogenesis and therapy of the acute coronary syndrome: differentiated advantage of glycoprotein IIb/IIIa receptor antagonists for high-risk patients
Activated thrombocytes and their aggregation into a thrombus play a decisive role in the pathogenesis of the acute coronary syndrome. Glycoprotein (GP) IIb/IIIa receptor antagonists block the binding of fibrinogen to GP IIb/IIIa receptors of activated thrombocytes and inhibit their aggregation. Patients with an acute coronary syndrome and raised troponin levels who are to undergo primary coronary revascularization profit particularly from treatment with GPIIb/IIIa receptor antagonists. This is especially so if they also have diabetes.

Literatur

• 1 Abrahamian H. Aggregationsneigung beim Diabetes mellitus.  Acta Med Austriaca. 1999;  5 137-141
• 2 Arjomand H, Roukoz B. et al . Platelets and antiplatelet therapy in patients with diabetes mellitus.  J Invas Cardiol. 2003;  15 264-269
• 3 Benamer H, Steg P G, Benessiano J. et al . Elevated cardiac troponin I predicts a high-risk angiographic anatomy of the culprit lesion in unstable angina.  Am Heart J. 1999;  137 815-820
• 4 Bollinger C, Schwenk B, Leschke M. Akutes Koronarsyndrom und Diabetes mellitus - eine Hochrisikokonstellation.  Klinikarzt. 2004;  33 193-297
• 5 Cannon C P, Weintraub W S, Demopoulos L A. et al . Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban.  N Engl J Med. 2001;  344 1879-1887
• 6 Chan A, Molitero D J. et al . Triple antiplatelet therapy during percutaneous coronary intervention is associated with improved outcomes including one-year survival.  J Am Coll Cardiol. 2003;  42 1188-1195
• 7 Chertow G M. et al . Survival after acute myocardial infarction in patients with end-stage renal disease.   Am Kidney Dis. 2000;  35 1044-1051
• 8 Erbel R, Heusch G. Coronary microembolization.  J Am Coll Cardiol. 2000;  36 22-24
• 9 Falk E. Unstable angina with fatal outcome: dynamic coronary thrombosis leading to infarction and/or sudden death.  Circulation. 1985;  71 699-708
• 10 Fernandez J S, Sadaniantz B, Sadaniantz A. Review of antithrombotic agents used for acute coronary syndromes in renal patients.  Am J Kidney Dis. 2003;  42 446-455
• 11 Freeman R V, Mehta R H, Al Badr W. et al . Influence of concurrent renal dysfunction on outcomes of patients with acute coronary syndromes and implications of the use of glycoprotein IIb/IIIa inhibitors.  J Am Coll Cardiol. 2003;  41 718-724
• 12 Heeschen C, von der Brand M J, Hamm C W, Simoons M L. for the CAPTURE investigators . Angiographic findings in patients with refractory unstable angina according troponin T status.  Circulation. 1999;  1000 1509-1514
• 13 Herzog C A, Ma J Z, Collins A J. Poor long-term survival after acute myocardial infarction among patients on long-term dialysis.  N Engl J Med. 1998;  339 799-805
• 14 Januzzi J L, Snapinn S M, Dibattiste P M. et al . Benefits and safety of tirofiban among acute coronary syndrome patients with mild to moderate renal insufficiency. Results from the PRISM-PLUS trial.  Circulation. 2002;  105 2361-2366
• 15 Kastrati A, Mehilli J, Neumann F J. et al . Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment: the ISAR-REACT 2 randomized trial.  JAMA. 2006;  295 1531-1538
• 16 Meinertz J, Rösen P, Schömig A, Tschöpe D, Ziegler D. (Hrsg.). Diabetes und Herz. 1. Auflage, Steinkopff 2004
• 17 Fachinformation Aggrastat® 250 Mikrogramm/ml. MSD Sharp & Dohme GmbH 2004
• 18 Morrow D A, Cannon C P, Rifai A. et al . Ability of minor elevations of troponins I and T to predict benefit from an early invasive strategy in patients with unstable angina and non-ST elevation myocardial infarction.  JAMA. 2001;  286 2405-2412
• 19 Münzel T, Daiber A, Ullrich V, Mulsch A. Vascular consequences of endothelial nitric oxide synthase uncoupling for the activity and expression of the soluble guanylyl cyclase and the cGMP-dependent protein kinase.  Arterioscler Thromb Vasc Biol. 2005;  25 1551-1557
• 20 O’Hanlon R, Reddan D N. Treatment of acute coronary syndromes in patients who have chronic kidney disease.  Med Clin N Am. 2005;  89 563-585
• 21 Osende J I, Badimon J J, Fuster V. et al . Blood thrombogenicity in type 2 diabetes mellitus is associated with glycemic control.  J Am Coll Cadiol. 2001;  38 1307-1312
• 22 Roffi M, Chew D P. et al . Platelet glycoprotein IIb/IIIa inhibitors reduce mortality in diabetic patients with non-ST-segment-elevation acute coronary syndromes.  Circulation. 2001;  104 2767-2771
• 23 Roffi M, Moliterno D J, Meier B. et al. for the TARGET investigators . Impact of different platelet glycoprotein IIb/IIIa inhibitors among diabetic patients undergoing percutaneous coronary intervention. Do Tirofiban or ReoPro Give Similar Efficacy Outcomes Trial (TARGET) 1-year-follow-up.  Circulation. 2002;  105 2730-2736
• 24 Schneider D J, Keating F K, Baumann P Q. et al . Increased ability of tirofiban to maintain its inhibitory effects on the binding of fibrinogen to platelets in blood from patients with and without diabetes mellitus.  Coron Artery Dis. 2006;  17 57-61
• 25 Shrape P C, Trinick T. Mean platelet volume in diabetes mellitus.  Q J Med. 1993;  86 739-742
• 26 Smith B S, Gandhi P J. Pharmacocinetics and pharmacodynamics of low-molecular-weight heparins and glycoprotein IIb/IIIa receptor agonists in renal failure.  J Thromb Thrombolysis. 2001;  11 39-48
• 27 Sreedhara R, Itagaki I, Hakim R M. Uremic patients have decrease shear-induced platelet aggregation mediated by a decreased availability of glycoprotein IIb/IIIa receptors.  Am J Kidney Dis. 1996;  27 355-364
• 28 Terres W. et al . Enhanced coagulation activation in troponin T-positive unstable angina pectoris.  Am Heart J. 1998;  135 281-286
• 29 The PRISM-PLUS Study Investigators . Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave-myocardial infarction.  N Engl J Med. 1998;  338 1488-1497
• 30 The PRISM Study Investigators . A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina.  N Engl J Med. 1998;  338 1498-1505
• 31 Tschoepe D, Rauch U, Schwippert B. Platelet-leucocyte-cross-talk in diabetes mellitus.  Horm Metab Res. 1997;  29 631-635
• 32 Tschoepe D, Roesen P, Kaufmann L. et al . Evidence for abnormal platelet glycoprotein expression in diabetes mellitus.  Eur J Clin Invest. 1990;  20 166-170
• 33 Valgimigli M, Campo G, Percoco G. et al . Tirofiban: a critical reappraisal of the clinical use, recent developments and future perspectives.  Future Cardiol. 2006;  2 17-27
• 34 International, randomized, controlled trial of lamifiban (a platelet glycoprotein IIb/IIIa inhibitor), heparin or both in unstable angina. The PARAGON Investigators . Platelet IIb/IIIa Antagonism for the Reduction of Acute coronary syndrome events in a Global Organization Network.  Circulation. 1998;  97 2386-2395
• 35 Moliterno DJ. Patient-specific dosing of IIb/IIIa antagonists during acute coronary syndromes: rationale and design of the PARAGON B study.  Am Heart J.. 2000;  139 563-566
• 36 Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. The PURSUIT Trial Investigators . Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Supression Using Integrilin Therapy.  N Engl J Med. 1998;  339 436-443
• 37 Simoons ML. Effect of glycoprotein IIb/IIIa receptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revascularisation: the GUSTO IV-ACS randomized trial.  Lancet. 2001;  357 1915-1924